|Day Low/High||80.81 / 81.57|
|52 Wk Low/High||66.75 / 89.13|
The chip maker sinks on news of production problems and a gloomy fourth-quarter prognosis.
The Swiss fertilizers maker says regulators in the EU and elsewhere have demanded more information.
Group sales of $2.5 billion were down 3 percent at constant exchange rates compared with the third quarter of 2015.
Syngenta closes down almost 6% after ChemChina missed an EU takeover deadline, while Italian lender Monte dei Paschi gains 28% on hopes of a rescue deal.
Syngenta (SYT) and ChemChina failed to provide remedies to EU antitrust regulators by Friday's deadline, which could delay the probe's timeline.
Beijing's apparent desire to see the companies merge adds uncertainty to ChemChina's $43 billion bid for the Swiss fertilizer maker.
- Steve Elfman, former President of Sprint, a major U.S. telecommunications company, to be appointed as Director, bringing extensive experience in the wireless industry
Syngenta has announced the completion of capacity expansion projects at key sites in Brazil and Switzerland.
Primary Culprits for Overspending Include Lack of Awareness for Automated Split Billing Solutions and Confusion in the C-Suite About Who Should Manage BYOD Programs
The agreement values the world's biggest seed maker at $128 per share and comes with a promise of $1.5 billion of annual synergies.
Monsanto shares should rise if the $129-per-share deal, including a massive break fee, is confirmed, while Bayer investors appear unsure whether to celebrate or mourn.
Bayer increases its latest offer to buy Monsanto, as regulators look closely at agribusiness mergers.
Bayer increases its latest offering to entice Monsanto, as regulators look closely at agribusiness mergers.
Monsanto previously rejected a bid of $125 per share, which Bayer said it could increase to up to $127.50 per share.
Even if the Dow merger with DuPont fails, Dow is in good shape.
The agrochemical company got a boost from U.S. regulators Monday, making a proposed $43 billion takeover more feasible.
Wall Street will get more clues on the Fed's rate hike plans later this week, but uncertainty over what they might be led to jittery trading on Monday.
Stocks fluctuate Monday afternoon as a selloff in crude oil hits the energy sector and Federal Reserve speeches at the end of the week leave investors wary.
Shares of Syngenta were charging ahead on news ChemChina received approval for its proposed takeover.
Stocks fall back into the red as a selloff in crude oil and gains in health care make for choppy trading.
Pfizer finalizes a deal to buy cancer drugmaker Medivation; ChemChina gets U.S. approval for its takeover of Syngenta; Viacom CEO Philippe Dauman is ousted.
U.S. interest rate talk weakens Japanese yen and spells better export opportunities, but the promotion of Reserve Bank of India deputy governor leaves the deputy's post open instead.
The two companies are still working with anti-trust regulators on the $44.7 billion deal.
Results from the ChemChina bid target come on the heels of disappointing figures from former suitor Monsanto.
Shares in the potential German seller rise sharply, despite some suspicions the talks are a negotiating ruse by the St. Louis company.
Talk of alternatives to Bayer's rejected $66 billion eclipsed disappointing third-quarter results.
Monsanto started the agribusiness/chemical merger trend with its pursuit of Syngenta. A year later, consolidation is rampant.